Tisdag 26 November | 05:46:00 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-17 09:00 Bokslutskommuniké 2024
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-07-31 - 15-6 2024
2024-05-23 - X-dag ordinarie utdelning NEOD 0.00 SEK
2024-05-22 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2024-02-16 - Split NEOD 100:1
2024-02-02 - Extra Bolagsstämma 2024
2023-11-27 - Kvartalsrapport 2023-Q3
2023-08-19 - Kvartalsrapport 2023-Q2
2023-07-27 - Extra Bolagsstämma 2023
2023-05-24 - X-dag ordinarie utdelning NEOD 0.00 SEK
2023-05-23 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning NEOD 0.00 SEK
2022-05-19 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-25 - Extra Bolagsstämma 2022
2022-02-16 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning NEOD 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-29 - X-dag ordinarie utdelning NEOD 0.00 SEK
2020-05-28 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-05 - Bokslutskommuniké 2019
2020-01-28 - Extra Bolagsstämma 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning NEOD 0.00 SEK
2019-05-23 - Årsstämma
2019-05-21 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neodynamics är verksamt inom medicinteknik. Idag är verksamheten inriktad mot att utveckla och kommersialisera produkter för behandling av kritiska sjukdomar. Via egenutvecklad mikropulsteknologi erbjuder bolaget precisionsbehandlingar mot bland annat cancer. Lösningarna används främst vid behandling avb bröstcancer hos kvinnor. Huvudkontoret ligger i Lidingö.
2024-06-17 17:45:00

The annual general meeting in NeoDynamics AB (publ) was held on 17 June 2024 at the company’s premises on Lejonvägen 14, Lidingö, whereby the shareholders primarily resolved on the following matters.

Annual report and result
The annual report and the auditor's report for the financial year 2023 were presented and the income statement and balance sheet included in the annual report were adopted.
It was resolved to not pay any dividends and that the company’s result shall be retained in the business.
 
Discharge from liability
The annual general meeting resolved to grant each of the members of the board of directors and the CEO discharge from liability in respect of the company for the financial year 2023.
 
Remuneration
It was resolved that no remuneration will be paid to the board.
It was further resolved that remuneration shall be paid to the auditor in accordance with approved invoice.
 
Board of directors
The annual general meeting resolved that the board shall consist of three (3) ordinary members without deputy members.
It was resolved to elect Mats Gustafsson and Erik Salén and reelect Matthew E. Colpoys, Jr., as board members for the period until the end of the next annual general meeting. Erik Salén was elected as chairman of the board.
 
Auditor
The annual general meeting resolved that one auditor, without deputy auditors, shall be appointed.
It was resolved to elect Ernst & Young AB (EY) as auditor, with Jakob Wojcik as principal auditor, for the period until the end of the next annual general meeting.
 
Authorizations
Directed issue(s)
The annual general meeting resolved to authorize the board of directors to, on one or several occasions during the period up to the next annual general meeting, increase the Company’s share capital through issues of new shares, warrants and/or convertible instruments, with or without provisions on payment by non-cash consideration and/or by way of set-off or other provisions. The board of directors shall not be able to make decisions that mean that the amount by which the share capital is increased corresponds to more than fifty (50) percent of the total share capital in the Company when the authorization is utilized for the first time.
 
Application on Delisting
The annual general meeting unanimously voted that NeoDynamics AB should apply for delisting.